Moxduo (QRx Pharma) resubmitted to the FDA for approval for Pain control

QRx Pharma has resubmitted its Moxduo (morphine plus oxycodone) New Drug Application (NDA) to the FDA for the control of Pain. The FDA confirmed that there were no efficacy or safety issues in any of the studies that were part of the original NDA. The resubmitted application, including new results from Study 022, will undergo review by an Advisory Committee to evaluate the approvability of Moxduo in the management of Pain.